Overview
Johnson & Johnson is a New Brunswick, New Jersey, holding company that researches, manufactures and sells health-care products through two segments, Innovative Medicine and MedTech.[2] It heads this ranking with Forbes sales of US$96.4bn, a figure that includes its medical-device business as well as prescription drugs; Forbes classifies the whole group under drugs and biotechnology.[2] The medicines segment covers immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolic disease and pulmonary hypertension, while MedTech sells interventional, orthopaedic, surgical and vision products.[2] In April 2025 Johnson & Johnson completed its acquisition of Intra-Cellular Therapies, adding the schizophrenia and bipolar-depression treatment Caplyta to its neuroscience portfolio.[6] With profit of US$21.0bn and a market value of US$545.7bn, it is also one of the three most valuable companies in the list.[2]
Johnson & Johnson strengths and limitations
Strengths
- Largest sales in the sector
- Two segments spread revenue across drugs and devices
- Profit margin above 20% on Forbes figures
Limitations
- Sales include medical devices, so the drug business alone is smaller
- Neuroscience expansion relied on a large acquisition
- Litigation exposure is a recurring feature of its filings
Appears in
Johnson & Johnson peers and competitors
Companies ranked in the same lists as Johnson & Johnson.
Roche Group
Takeda Pharmaceutical
Daiichi Sankyo- Astellas Pharma
Viatris- Regeneron Pharmaceuticals
- CSL
Otsuka Holdings- Teva Pharmaceutical
Merck KGaA
Gilead Sciences- Amgen
Is this your company?
Update the description, logo, image and link through the submission form. Editors review every change.